Tocilizumab reduces COVID-19 mortality and pathology in a dose and timing-dependent fashion: a multi-centric study

Life-threatening COVID-19 is associated with strong inflammation, where an IL-6-driven cytokine storm appears to be a cornerstone for enhanced pathology. Nonetheless, the specific inhibition of such pathway has shown mixed outcomes. This could be due to variations in the dose of tocilizumab used, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Durán-Méndez, Alejandro, Aguilar-Arroyo, Alma Delia, Vivanco-Gómez, Emiliano, Nieto-Ortega, Eduardo, Pérez-Ortega, Daniela, Jiménez-Pérez, Cristian, Hernández-Skewes, Karla Y., Montiel-Bravo, Guillermo, Roque-Reyes, Oscar J., Romero-Lechuga, Fernanda, Medina-Santos, Diana, Oriana-Román, Perla, Flores-Hernández, Jorge Rafael, Méndez-Coca, Juan Daniel, Montaño-Olmos, Daniela, Farfán-Lazos, Karla Cecilia, Tobón-Cubillos, Miranda, Viveros-Hernández, América, Sevilla-Castillo, Fernando, Hernández-Romero, Ángel Raúl, Ortega-Rodríguez, Shannat, Jardínez-Vera, Aldo Christiaan, Solís-González, María Antonieta, de la Medina, Antonio Ramos, Pérez-Maldonado, Laura Martínez, Lagunes-Lara, Elizabeth, Cova-Bonilla, Miguel, Peón, Alberto N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492686/
https://www.ncbi.nlm.nih.gov/pubmed/34611251
http://dx.doi.org/10.1038/s41598-021-99291-z

Ejemplares similares

Ejemplares similares